Business Wire

Panasonic's Multi-hop HD-PLC Adopted as Smart Meter Communications System by Taiwan Power Company

Share

Panasonic Corporation has successfully proposed adoption to Taiwan Power Company of its HD-PLC (*1) high-speed power line communications technology as a communications system to utilize next-generation smart meters.

Taiwan Power Company began accepting proposals for technology relating to communications systems in June 2017. Verification testing of the latest wireless technology and power line communications technology was held in Taipei City in September of that year. Smart meters will be introduced to approx. 260,000 households in main cities of Taiwan from December 2018. The HD-PLC technology meets the high performance criteria required, and smart meters incorporating this technology will be introduced in Taipei and other areas.

Smart meters require stable communications performance to achieve detailed controls matching power demand with high-frequency data collection. The HD-PLC technology can meet these requirements and is expected to contribute to building IoT communications infrastructure for smart meters and smart city concepts to be adopted worldwide in the future.

[Overview of the verification testing]
The verification testing at Taiwan Power Company conducted as follows:

  • A data collection rate of 99% at 15 minute intervals was required to evaluate the communications performance between the smart meters and the power company data collection center.
  • Evaluation of smart meter installation conditions in various situations such as a case installed under the eaves of detached houses, and a case of each meter installed in a basement room for commercial buildings or condominiums.

The HD-PLC technology conforms to the IEEE 1901 (*2) international standard as well as to ITU-T G.9905 multi-hop technology for relay functions, allowing communication of several Mbps over long distances. The testing verified that power lines could transmit from middle and high voltage transformers placed on roads to meters below buildings. A data collection rate of 100% was achieved during the testing period to successfully pass the test.

Panasonic will continue to develop the HD-PLC technology while pursuing convenience for users in order to realize a smart IoT society in the future. Panasonic is also seeking to secure interconnectivity between products conforming to the IEEE 1901 through organizations such as the HD-PLC Alliance (*3), to provide globally HD-PLC-equipped products that users can utilize in safety.

Notes
*1 HD-PLC stands for High Definition Power Line Communication, as advocated by Panasonic. This is a trademark or a registered trademark in Japan and other nations.

*2 A standardization committee for communications standards under the Institute of Electrical and Electronics Engineers (IEEE).

*3 Established on September 25, 2007 with the aim of securing the expansion and communications compatibility of HD-PLC.
Website: http://www.hd-plc.org/

Source:
https://news.panasonic.com/global/press/data/2018/09/en180925-2/en180925-2.html

Related Links
HD-PLC Alliance
http://www.hd-plc.org/

[Press Release] Panasonic Next-Generation PLC Technology Approved as Baseline Specification by IEEE P1901.3 Working Group (Jun 29, 2018)
https://news.panasonic.com/global/press/data/2018/06/en180629-2/en180629-2.html

[Press Release] Panasonic starts to provide HD-PLC IP core license with "Multi-hop" extension (Jul 01, 2016)
https://news.panasonic.com/global/press/data/2016/07/en160701-2/en160701-2.html

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Panasonic Corporation
Global Communications Department
Global PR Office
Click here to go to Media Contact form

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 19:03:00 EEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 18:43:00 EEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 18:22:00 EEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/ Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 15:30:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 15:00:00 EEST | Press release

The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye